LBRX — LB Pharmaceuticals Balance Sheet
0.000.00%
- $736.66m
- $441.44m
Annual balance sheet for LB Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Cash and Equivalents | |||
| Short Term Investments | |||
| Cash and Short Term Investments | 43.3 | 28 | 295 |
| Prepaid Expenses | |||
| Total Other Current Assets | |||
| Total Current Assets | 45.6 | 28.9 | 308 |
| Gross Property, Plant And Equipment | |||
| Accumulated Depreciation | |||
| Net Property, Plant And Equipment | 0.023 | 4.16 | 3.73 |
| Other Long Term Assets | |||
| Total Assets | 45.7 | 33.5 | 313 |
| Accounts Payable | |||
| Accrued Expenses | |||
| Notes Payable / Short Term Debt | |||
| Total Current Liabilities | 2.61 | 8.11 | 7.44 |
| Total Long Term Debt | |||
| Total Debt | |||
| Total Other Liabilities | |||
| Total Liabilities | 4.16 | 13.8 | 11.6 |
| Redeemable Preferred Stock | |||
| Common Stock | |||
| Additional Paid In Capital | |||
| Retained Earnings (Accumulated Deficit) | |||
| Other Equity | |||
| Total Equity | 41.5 | 19.7 | 301 |
| Total Liabilities & Shareholders' Equity | 45.7 | 33.5 | 313 |
| Total Common Shares Outstanding |